H.C. Wainwright analyst Joseph Pantginis raised his price target for Aptose Biosciences (APTO) to $9 from $6 and keeps a Buy rating on the shares.
Aptose’s shares have been starting to reflect the promise of CG-806, as the Street is realizing that CG-806 is not just a double FLT3/BTK inhibitor but also a mutationagnostic compound with the potential of gaining significant market share over approved drugs in several hematology-oncology malignancies, Pantginis tells investors in a research note.
According to TipRanks, Pantginis has a 45% success rate with an average return of 12.8%.
Pantiginis covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals, Aduro Biotech, and Onconova Therapeutics.
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $8.50, a 13.4% upside from current levels. In a report released this week, JonesTrading also maintained a Buy rating on the stock with a $12 price target.
